Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIMTA and bevacizumab in second-line NSCLC
NCT00268489Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2006
- Primary completion
- May 2007
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Started May 2006; status: completed.
02
Drugs
pemetrexedbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00268489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268489.